A large study recruited patients from multiple nations in four cohorts receiving CD19 targeted CAR Ts with TRAC and β2M KO for relapsed/refractory B cell malignancies (A-C: NHL, D: B-ALL) and was terminated early in phase II [249]. This evidence concerns the gene B2M and acute lymphoblastic leukemia.